Taipei, Taiwan (AP) — Chinese vaccine makers are considering whether jab mixing and booster shots can help strengthen protection from COVID-19.
The two Chinese manufacturers, Sinovac and Sinopharm, have exported hundreds of millions of vaccines worldwide and are considering combining their vaccines with those of other companies.
Earlier this month, China’s Centers for Disease Control and Prevention said Takafuku said that current vaccines have low protection against coronavirus and that mixing them is one of the strategies being considered to increase their effectiveness. Said.
Gao later tried to comment back, saying he was generally talking about improving the effectiveness of the vaccine.
China’s National Biotechnology Group has plans for future “sequential use” of the vaccine, Lee Meng, head of the company’s international cooperation, said at an international conference Wednesday.
The company, a subsidiary of state-owned Sinopharm, produced two inactivated COVID-19 vaccines, the third in clinical trials.
Beijing-based private sector Sinovac also said it is in preliminary discussions with researchers, including the Centers for Disease Control and Prevention, on how to combine doses of the vaccine CoronaVac with others.
Ashley St. John, an immunologist at Duke NUS Medical College in Singapore, said continuous vaccination meant mixing different vaccines, a strategy that could increase efficacy.
“They are trying to fine-tune their schedule to really find the best points to vaccinate people,” said St. John. “What is the best combination and time point?”
The company’s Beijing Biological Products Research Institute and Wuhan Biological Products Research Institute’s Sinopharm vaccines are 79% and 72% effective, respectively, the company said. Data from the final stages of clinical trials have not been published.
This practice is also being considered in other countries. British scientists are studying a combination of AstraZeneca and Pfizer shots. This study also aims to test different intervals between doses at 4-week and 12-week intervals.
The results of such studies could impact public health around the world as governments around the world delay timely access to vaccines and face logistic hurdles in deploying shots. there is.
Brazilian researchers who conducted a clinical trial of Sinovac in Brazil released new data this month reaffirming the company’s previously announced 50% efficacy rate. The paper, which has not yet been peer-reviewed but published on a scientist website, shows that the Sinovac vaccine is 50.7% effective in symptomatological COVID-19 cases and is much more potent against serious illness. I showed that.
CanSino, another Chinese company that created the adenovirus vector vaccine, said it was investigating the effects of booster vaccination with its own vaccine six months after the initial dose. Shots using the same technique as AstraZeneca’s shots are 65.3% effective.